Clinical Trials

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

By

In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

By

Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.

Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With Cancer

By

A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.

Surrogate End Points Are Poor Predictors of Survival in Cancer Drug Approval

By

US FDA standards demand that surrogate end points used in clinical trials be "reasonably likely to predict" survival for accelerated approval, or be established proxies for survival for traditional approval; however, surrogate end points used frequently lack formal study.

Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma

By

Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.

Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma

Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma

By

A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

By

An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.

Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication

Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication

By

Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

By

NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.

Precision Medicine Linked to Better Outcomes in Early Trials

Precision Medicine Linked to Better Outcomes in Early Trials

By

Patients whose treatment was based on the molecular characteristics of their particular tumor had significantly better outcomes compared with patients who did not.

Many Americans Have Reservations About Clinical Trials

Many Americans Have Reservations About Clinical Trials

Only 40 percent of those polled had favorable view of these studies, but the number rose when they received more information.

Chemoradiotherapy Showed No Survival Benefit Over Chemotherapy in Locally Advanced Pancreatic Cancer

By

Researchers discovered no survival benefit of chemoradiotherapy over chemotherapy in treating locally advanced pancreatic cancer in the LAP01 Randomized Clinical Trial.

Experimental Targeted Therapy Succeeds in Rare Pediatric Cancer

By

The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.

Tumor Regression Achieved With LOXO-101 in Phase 1 Study

By

Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.

Research Unit Aims To Train Nurses to Provide Better Care to Clinical Trial Patients

Research Unit Aims To Train Nurses to Provide Better Care to Clinical Trial Patients

By

A research unit created by oncology nurses trains nurses to provide high quality care to patients in oncology clinical trials.

Clinical Trial Infusion Nurse Orientation Improves Care for Patients in Investigational Studies

Clinical Trial Infusion Nurse Orientation Improves Care for Patients in Investigational Studies

By

A clinical trial infusion nurse orientation improves training for nurses so they can better care for patients participating in investigational trials.

Antibody Therapy Reduces Numbers of Cancer Stem Cells in Patients With Multiple Myeloma

Antibody Therapy Reduces Numbers of Cancer Stem Cells in Patients With Multiple Myeloma

By

Cancer stem cells that drive tumor growth were halved by MEDI-551, an experimental antibody treatment for multiple myeloma, according to results of a small preliminary clinical trial.

Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer

Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer

By

Treatment with a hypofractionated radiotherapy (HRT) schedule achieved similar efficacy as treatment with the longer, conventional RT (CRT) schedule in men with low-risk prostate cancer.

Radiotherapy/Histone Deacetylase Inhibitor Combination Safe, Effective in High-grade Gliomas

By

Adding panobinostat to radiotherapy appears safe, tolerable, and has preliminary efficacy for treating recurrent high-grade gliomas.

Social Media Has Unrealized Potential for Clinical Trial Communication and Recruitment

Social Media Has Unrealized Potential for Clinical Trial Communication and Recruitment

By

The social media platform Twitter could develop into a useful tool for communicating with the public about cancer clinical trials and for recruiting participants.

Combination of Immune Checkpoint Blockers Shows Promise in Lung Cancer

By

Combination therapy with durvalumab and tremelimumab demonstrated antitumor activity in 23% of 102 patients with lung cancer in a phase 1b trial, and toxicity was manageable.

Interferon Has Little Benefit for Patients With Small Amounts of Melanoma in the Lymph Nodes

Interferon Has Little Benefit for Patients With Small Amounts of Melanoma in the Lymph Nodes

By

No evidence that interferon is necessary or helpful in cases of melanoma with minimal metastasis to the lymph nodes, according to the final results of the Sunbelt Melanoma Trial.

Targeted Hormone-radiation Treatment Shows Promise in Midgut Neuroendocrine Tumors

By

Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.

Optical Probes That Illuminate Solid Tumors in Surgery Move One Step Closer to Reality

Optical Probes That Illuminate Solid Tumors in Surgery Move One Step Closer to Reality

By

Optical probes that make cancer cells glow and improve surgical tumor removal are in phase I and II clinical trials in humans. The probes could be commonplace in the next 5 to 10 years, hypothesize the researchers.

Mapping Tumor Position During Lung Function Improves Radiation Therapy for Lung Cancer

Mapping Tumor Position During Lung Function Improves Radiation Therapy for Lung Cancer

By

A new clinical trial aims to apply advanced image analysis techniques to 4D CT scans. Already a standard step in targeting lung cancer radiotherapy, the trial seeks to use the scans map areas of lung function without additional testing.

Certain Characteristics of Clinical Trials May Predict Poor Accrual of Participants

By

Researchers identified characteristics that may lead to low patient accrual for a clinical trial.

No Need to Exclude Patients With Renal Insufficiency From Clinical Trials

By

Excluding patients with renal insufficiency but good performance status from clinical trials due to concern of excessive hematologic toxicity or poor outcomes may not be necessary with appropriate dosing modifications.

Mandatory Biopsy May Hinder Eligibility of Potential Participants in Cancer-related Clinical Trials

By

Mandatory tumor tissue specimens and associated analyses for clinical trial participation appear to be a significant barrier to clinical trial enrollment and may delay treatment.

Pembrolizumab Increases Overall Survival for PD-L1-positive, Advanced Non-small Cell Lung Cancer

By

A recent study examined the efficacy of pembrolizumab for the treatment of previously treated, PD-L1-positive, advanced non-small-cell lung cancer.

Extra Biopsies in Clinical Trials Often Have No Impact on Drug Dose or Use in Cancer Treatments

By

Extra biopsies performed solely to study the pharmacodynamics of a new anticancer drug have no impact on subsequent drug development or on how physicians use these new drugs to treat future patients.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs